Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $127.78 +0.65 (+0.51%) (As of 09/20/2024 08:54 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Natera Stock (NASDAQ:NTRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$124.79▼$128.4050-Day Range$97.75▼$129.6752-Week Range$36.90▼$132.01Volume2.19 million shsAverage Volume1.37 million shsMarket Capitalization$15.69 billionP/E RatioN/ADividend YieldN/APrice Target$120.07Consensus RatingBuy Company OverviewNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More… The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.Download my Dividend Calendar here Natera Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 35th PercentileNatera scored higher than 35% of companies evaluated by MarketBeat, and ranked 769th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.96) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 20.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.03% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Natera has recently decreased by 2.89%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.03% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Natera has recently decreased by 2.89%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.54 News SentimentNatera has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Natera this week, compared to 7 articles on an average week.Search InterestOnly 6 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,551,281.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. NTRA Stock News HeadlinesInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of StockSeptember 21 at 8:36 AM | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CEO Sells $645,483.52 in StockSeptember 20 at 8:40 AM | insidertrades.com Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!September 23, 2024 | Paradigm Press (Ad)Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman Sells 2,614 SharesSeptember 17, 2024 | insidertrades.comBrokerages Set Natera, Inc. (NASDAQ:NTRA) Target Price at $120.07September 23 at 3:35 AM | americanbankingnews.comNatera co-founder sells over $2.8 million in company stockSeptember 21 at 6:39 AM | in.investing.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $344,439.00 in StockSeptember 21 at 2:55 AM | americanbankingnews.comNatera (NASDAQ:NTRA) Reaches New 1-Year High at $133.00September 19, 2024 | americanbankingnews.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 at the start of the year. Since then, NTRA stock has increased by 104.0% and is now trading at $127.78. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.39. The company's quarterly revenue was up 58.1% on a year-over-year basis. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's top institutional investors include Fred Alger Management LLC (4.29%), Farallon Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.95%) and Duquesne Family Office LLC (1.61%). Insiders that own company stock include Matthew Rabinowitz, Jonathan Sheena, Daniel Rabinowitz, Steven Leonard Chapman, Solomon Moshkevich, John Fesko, Michael Burkes Brophy, Herm Rosenman, James Healy, Gail Boxer Marcus, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV) and Aegean Marine Petroleum Network (ANW). Company Calendar Last Earnings8/08/2024Today9/23/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$120.07 High Stock Price Target$150.00 Low Stock Price Target$70.00 Potential Upside/Downside-6.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-21.47% Pretax Margin-21.35% Return on Equity-36.74% Return on Assets-19.90% Debt Debt-to-Equity Ratio0.34 Current Ratio4.14 Quick Ratio4.01 Sales & Book Value Annual Sales$1.36 billion Price / Sales11.53 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book20.06Miscellaneous Outstanding Shares122,803,000Free Float113,470,000Market Cap$15.69 billion OptionableOptionable Beta1.53 This page (NASDAQ:NTRA) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Natera, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.